Compare · BDSX vs CNC
BDSX vs CNC
Side-by-side comparison of Biodesix Inc. (BDSX) and Centene Corporation (CNC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDSX and CNC operate in Medical Specialities (Health Care), so they compete in similar markets.
- CNC is the larger of the two at $32.11B, about 108.4x BDSX ($296.2M).
- CNC has been more active in the news (12 items in the past 4 weeks vs 6 for BDSX).
- CNC has more recent analyst coverage (25 ratings vs 9 for BDSX).
- Company
- Biodesix Inc.
- Centene Corporation
- Price
- -
- -
- Market cap
- $296.2M
- $32.11B
- 1M return
- +39.09%
- -
- 1Y return
- +220.29%
- -
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 6
- 12
- Recent ratings
- 9
- 25
Biodesix Inc.
Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company offers blood-based tests across the lung cancer continuum of care, such as Nodify XL2 and Nodify CDT tests to help physicians reclassify risk of malignancy in patients with suspicious lung nodules; and GeneStrat tumor profiling and VeriStrat immune profiling tests that provide physicians with timely results to facilitate treatment decisions. It also provides Bio-Rad SARS-CoV-2 ddPCR test, which is designed to detect the presence of infection by the SARS-CoV-2 virus; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. In addition, the company offers include diagnostic research, clinical research, development, and testing services to biopharmaceutical companies, as well as discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
Centene Corporation
Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members in the Managed Care segment. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; and vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
Latest BDSX
- Emeritus Director Schuler Jack W bought $366,992 worth of shares (15,000 units at $24.47) (SEC Form 4)
- Emeritus Director Schuler Jack W bought $665,940 worth of shares (27,600 units at $24.13) (SEC Form 4)
- SEC Form 10-Q filed by Biodesix Inc.
- Biodesix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biodesix Announces Second Quarter 2026 Results and Highlights
- Biodesix to Participate in Canaccord Genuity’s 46th Annual Growth Conference
- Biodesix to Report Second Quarter 2026 Financial Results on August 5, 2026
- Chairman Patience John converted options into 1,361 shares, increasing direct ownership by 6% to 25,383 units (SEC Form 4)
- Roth Capital initiated coverage on Biodesix with a new price target
- H.C. Wainwright initiated coverage on Biodesix with a new price target
Latest CNC
- California Community Health Workers and Doulas Can Spend More Time Helping Medi-Cal Members, Thanks to Health Net's $900,000 Grant to Pear Suite
- Coordinated Care Brings Free Health Screenings to Washington Communities with Statewide Vision & Dental Van Tour
- Superior HealthPlan has supported more than 312,000 Texas pregnancies since 2022 through the Start Smart for Your Baby® program
- Secretary & General Counsel Koster Christopher sold $3,111,332 worth of shares (47,603 units at $65.36), decreasing direct ownership by 13% to 305,354 units (SEC Form 4)
- Centene Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Centene Announces Planned Chief Financial Officer Transition
- Sixty Compton, California Students to be Selected for Leadership and Health Advocacy Training, Powered by Health Net's $412,000 Investment
- Carolina Complete Health Supports Young Leaders Through AMEXCAN Summer Camp
- MHS Serves Announces Recipients of over $2 Million Investment in Hoosier Employment
- Health Net Providing Special Assistance to Members and Providers Affected by Gann Fire in Calaveras County